Table 1.
Costing and description of direct costs.
Table 2.
Cost of the public health system with the assistance to hypertensive patients in the follow-up years of the study.
Fig 1.
A) Cost-effectiveness plan of pharmaceutical care for years; B) Cost-effectiveness plan of pharmaceutical care for period. By period the mean cost and pressure control percentage of their years was used to compare periods of pharmaceutical care and post pharmaceutical care with the pre-pharmaceutical care period.
Table 3.
Cost effectiveness ratio and incremental cost effectiveness ratio analysis per year and period considering the cost of embedded pharmaceutical care in the cost of the public health system with assistance to hypertensive patients.
Fig 2.
Cost-effectiveness threshold based on the pre-PC cost-effectiveness trend line.
Fig 3.
Analysis of the one-way sensitivity performed by the incremental net benefit to pharmaceutical care.
INB = Incremental net-benefit. A) Structuring the sensitivity analysis of the incremental net benefit to pharmaceutical care, considering the minimum value of 1 dollar and maximum of 3 x GDP per capita of Brazil used as threshold for the willingness to pay for pharmaceutical care; B) Sensitivity analysis for the incremental net benefit to pharmaceutical care, considering the spending with pharmaceutical care as the willingness to pay for pharmaceutical care after discharge of patients. The maximum value used as a threshold for willingness to pay was the cost of pharmaceutical care calculated in this study. Negative INB values represent a non-compensatory valuation of PC for investment, and positive INB values represent valuation that is compensatory as investment.
Fig 4.
Monte Carlo simulation sensitivity analysis for the ratio of cost effectiveness and the ratio of incremental cost effectiveness in the period.
Pre-PC period = baseline; A) Monte Carlo simulation sensitivity analysis for ratio of cost effectiveness of pharmaceutical care compared to baseline; B) Monte Carlo simulation sensitivity analysis for ratio of incremental cost effectiveness of pharmaceutical care compared to baseline; C) Sensitivity analysis by Monte Carlo simulation for ratio of cost effectiveness post pharmaceutical care compared to baseline; D) Sensitivity analysis by Monte Carlo simulation for ratio of incremental cost effectiveness for post pharmaceutical care compared to baseline. 10,000 iterations were performed in Monte Carlo simulation to evaluate the variation of the values of the ratio of cost effectiveness and the ratio of incremental cost effectiveness on the variation of costs by pertinent patient to the probability distribution of costs and pressure control percentage of outcome for each baseline year, for the year of pharmaceutical care, and each year after pharmaceutical care. It can be highlighted that after pharmaceutical care there is not the cost of pharmaceutical care for the calculation of the ratios, thus, the ratios reflect the conventional cost for the care of hypertensive patients’ health in the Public Health System as baseline, compared to the result of pharmaceutical care on conventional health costs. Monte Carlo simulations for CER were structured to represent the probability of CER in the PC and post-PC periods being greater than the baseline CER, thus part A) reflects the result of CER difference of the PC period minus the baseline CER period and part C) reflects the result of the difference of the post-PC CER period minus the baseline CER period.